nach oben

Indian Journal of Surgical Oncology

Erschienen in:

17.12.2016 | Review Article

Current Concepts in Management of Stage I NSGCT

verfasst von: Puneet Ahluwalia, Gagan Gautam

Erschienen in: Indian Journal of Surgical Oncology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

While about 50% of non- seminomatous germ cell tumors of the testes present as clinical stage I (CSI), further management of these patients continues to be mired in controversy. Active surveillance is a frontline option for low- risk CS I patients and according to some, even the high- risk ones with high embryonal carcinoma (ECA) component and vascular invasion (VI). However, it carries the disadvantage of long- term surveillance, the need for prolonged chemotherapy in case of recurrence and the possibility of secondary malignancies due to radiation exposure from frequent CT scans. One or two cycles of BEP chemotherapy is a popular alternative to active surveillance which carries a very low relapse rate, but valid concerns about overtreatment of a majority of patients, with the attendant chemotherapy- related toxicity exist. Retroperitoneal lymph node dissection has been used as a means of avoiding chemotherapy, especially in high- risk patients, but carries the disadvantage of a high surgical morbidity and complications. As with any major surgical procedure, the best results are dependent on the experience and skill of the individual surgeon.

Read G, Stenning SP, Cullen MH, Parkinson MC, Horwich A, Kaye SB et al (1992) Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council testicular tumors working party. J Clin Oncol 10(11):1762–1768PubMed

Daugaard G, Petersen PM, Rorth M. Surveillance in stage I testicular cancer. APMIS. 2003;111(1):76–83; discussion −5.

Colls BM, Harvey VJ, Skelton L, Frampton CM, Thompson PI, Bennett M et al (1999) Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years’ experience in a national study in New Zealand. BJU Int 83(1):76–82CrossRefPubMed

de Wit R, Fizazi K (2006) Controversies in the management of clinical stage I testis cancer. J Clin Oncol 24(35):5482–5492CrossRefPubMed

Krug B, Heidenreich A, Dietlein M, Lackner K (1999) The lymph node staging of malignant testicular germ-cell tumors. Rofo 171(2):87–94PubMed

Barentsz J, Takahashi S, Oyen W, Mus R, De Mulder P, Reznek R et al (2006) Commonly used imaging techniques for diagnosis and staging. J Clin Oncol 24(20):3234–3244CrossRefPubMed

White PM, Adamson DJ, Howard GC, Wright AR (1999) Imaging of the thorax in the management of germ cell testicular tumours. Clin Radiol 54(4):207–211CrossRefPubMed

Meyer CA, Conces DJ (2002) Imaging of intrathoracic metastases of nonseminomatous germ cell tumors. Chest Surg Clin N Am 12(4):717–738CrossRefPubMed

Hogeboom WR, Hoekstra HJ, Mooyaart EL, Sleijfer DT, Schraffordt KH (1993) Magnetic resonance imaging of retroperitoneal lymph node metastases of non-seminomatous germ cell tumours of the testis. Eur J Surg Oncol 19(5):429–437PubMed

10.

de Wit M, Brenner W, Hartmann M, Kotzerke J, Hellwig D, Lehmann J et al (2008) [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol 19(9):1619–1623CrossRefPubMed

11.

Huddart RA, O’Doherty MJ, Padhani A, Rustin GJ, Mead GM, Joffe JK et al (2007) 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22—the NCRI Testis Tumour Clinical Study Group. J Clin Oncol 25(21):3090–3095CrossRefPubMed

12.

Freedman LS, Parkinson MC, Jones WG, Oliver RT, Peckham MJ, Read G et al (1987) Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 2(8554):294–298CrossRefPubMed

13.

Raghavan D, Peckham MJ, Heyderman E, Tobias JS, Austin DE (1982) Prognostic factors in clinical stage I non-seminomatous germ-cell tumours of the testis. Br J Cancer 45(2):167–173CrossRefPubMedPubMedCentral

14.

Sturgeon JF, Jewett MA, Alison RE, Gospodarowicz MK, Blend R, Herman S et al (1992) Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors. J Clin Oncol 10(4):564–568PubMed

15.

Roeleveld TA, Horenblas S, Meinhardt W, van de Vijver M, Kooi M, ten Bokkel Huinink WW (2001) Surveillance can be the standard of care for stage I nonseminomatous testicular tumors and even high risk patients. J Urol 166(6):2166–2170CrossRefPubMed

16.

Alexandre J, Fizazi K, Mahe C, Culine S, Droz JP, Theodore C et al (2001) Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse. Eur J Cancer 37(5):576–582CrossRefPubMed

17.

Gels ME, Hoekstra HJ, Sleijfer DT, Marrink J, de Bruijn HW, Molenaar WM et al (1995) Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol 13(5):1188–1194PubMed

18.

Vergouwe Y, Steyerberg EW, Eijkemans MJ, Albers P, Habbema JD (2003) Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J Clin Oncol 21(22):4092–4099CrossRefPubMed

19.

Divrik RT, Akdogan B, Ozen H, Zorlu F (2006) Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors—is shift to risk adapted policy justified? J Urol 176(4 Pt 1):1424–1429 discussion 9-30CrossRefPubMed

20.

Duran JF, Jewett MA, Anson-Cartwright L, Berthold DR, Kakiashvili D, Warde PR, Alison RE, Pond GR, Moore MJ (2007) Initial versus recent outcomes with a non–risk adapted surveillance policy in stage I non seminomatous germ cell tumors (NSGCT). J Clin Oncol 25(18S):240

21.

Sogani PC, Perrotti M, Herr HW, Fair WR, Thaler HT, Bosl G (1998) Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol 159(3):855–858CrossRefPubMed

22.

Droz JP, van Oosterom AT (1993) Treatment options in clinical stage I non-seminomatous germ cell tumours of the testis: a wager on the future? A review Eur J Cancer 29A(7):1038–1044CrossRefPubMed

23.

Heidenreich A, Sesterhenn IA, Mostofi FK, Moul JW (1998) Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 83(5):1002–1011CrossRefPubMed

24.

Albers P, Siener R, Kliesch S, Weissbach L, Krege S, Sparwasser C et al (2003) Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group trial. J Clin Oncol 21(8):1505–1512CrossRefPubMed

25.

Oliver RT, Ong J, Shamash J, Ravi R, Nagund V, Harper P et al (2004) Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with stage 1 nonseminoma treated with adjuvant chemotherapy. Urology 63(3):556–561CrossRefPubMed

26.

Zuniga A, Kakiashvili D, Jewett MA (2009). Surveillance in stage I nonseminomatous germ cell tumours of the testis. BJU Int.;104(9 Pt B):1351–6

27.

Spermon JR, Roeleveld TA, van der Poel HG, Hulsbergen-van de Kaa CA, ten Bokkel Huinink WW, van de Vijver M et al (2002) Comparison of surveillance and retroperitoneal lymph node dissection in stage I nonseminomatous germ cell tumors. Urology 59(6):923–929CrossRefPubMed

28.

Maroto P, Garcia del Muro X, Aparicio J, Paz-Ares L, Arranz JA, Guma J et al (2005) Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours. Ann Oncol 16(12):1915–1920CrossRefPubMed

29.

Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F et al (2008) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part I. Eur Urol 53(3):478–496CrossRefPubMed

30.

Tarin TV, Sonn G, Shinghal R (2009) Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J Urol 181(2):627–632 discussion 32-3CrossRefPubMed

31.

Atsu N, Eskicorapci S, Uner A, Ekici S, Gungen Y, Erkan I et al (2003) A novel surveillance protocol for stage I nonseminomatous germ cell testicular tumours. BJU Int 92(1):32–35CrossRefPubMed

32.

Rustin GJ, Mead GM, Stenning SP, Vasey PA, Aass N, Huddart RA et al (2007) Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197—the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 25(11):1310–1315CrossRefPubMed

33.

Cullen MH, Stenning SP, Parkinson MC, Fossa SD, Kaye SB, Horwich AH et al (1996) Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 14(4):1106–1113PubMed

34.

Oliver RT, Raja MA, Ong J, Gallagher CJ (1992) Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage 1 malignant teratoma on overall relapse rate of stage 1 cancer patients. J Urol 148(5):1453–1455 discussion 5-6PubMed

35.

Studer UE, Fey MF, Calderoni A, Kraft R, Mazzucchelli L, Sonntag RW (1993) Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer. Eur Urol 23(4):444–449PubMed

36.

Bohlen D, Borner M, Sonntag RW, Fey MF, Studer UE (1999) Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 161(4):1148–1152CrossRefPubMed

37.

Pont J, Albrecht W, Postner G, Sellner F, Angel K, Holtl W (1996) Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 14(2):441–448PubMed

38.

Chevreau C, Mazerolles C, Soulie M, Gaspard MH, Mourey L, Bujan L et al (2004) Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol 46(2):209–214 discussion 14-5CrossRefPubMed

39.

Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-Stahl E, Stierner U, Solberg A et al (2009) Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 27(13):2122–2128CrossRefPubMed

40.

Tandstad T, Stahl O, Hakansson U, Dahl O, Haugnes HS, Klepp OH et al (2014) One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol 25(11):2167–2172CrossRefPubMed

41.

Klepp O, Dahl O, Flodgren P, Stierner U, Olsson AM, Oldbring J et al (1997) Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer. Eur J Cancer 33(7):1038–1044CrossRefPubMed

42.

Ondrus D, Matoska J, Belan V, Kausitz J, Goncalves F, Hornak M (1998) Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment. Eur Urol 33(6):562–566CrossRefPubMed

43.

Tandstad T, Cohn-Cedermark G, Dahl O, Stierner U, Cavallin-Stahl E, Bremnes RM et al (2010) Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study Ann Oncol 21(9):1858–1863CrossRefPubMed

44.

Kollmannsberger C, Moore C, Chi KN, Murray N, Daneshmand S, Gleave M et al (2010) Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol 21(6):1296–1301CrossRefPubMed

45.

Kakiashvili DM, Zuniga A, Jewett MA (2009) High risk NSGCT: case for surveillance. World J Urol 27(4):441–447CrossRefPubMed

46.

Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF et al (2005) Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 23(12):2781–2788CrossRefPubMed

47.

Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Horwich A et al (2005) Guidelines on testicular cancer. Eur Urol 48(6):885–894CrossRefPubMed

48.

Dearnaley DP, Fossa SD, Kaye SB, Cullen MH, Harland SJ, Sokal MP et al (2005) Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17). Br J Cancer 92(12):2107–2113CrossRefPubMedPubMedCentral

49.

Pectasides D, Skarlos D, Dimopoulos AM, Farmakis D, Pectasides M, Fountzilas G et al (2003) Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial. Anticancer Res 23(5b):4239–4244PubMed

50.

Horwich A, Sleijfer DT, Fossa SD, Kaye SB, Oliver RT, Cullen MH et al (1997) Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15(5):1844–1852PubMed

51.

Fossa SD, Aass N, Winderen M, Bormer OP, Olsen DR (2002) Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol 13(2):222–228CrossRefPubMed

52.

Meinardi MT, Gietema JA, van der Graaf WT, van Veldhuisen DJ, Runne MA, Sluiter WJ et al (2000) Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18(8):1725–1732PubMed

53.

Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J et al (2003) Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21(8):1513–1523CrossRefPubMed

54.

Sagstuen H, Aass N, Fossa SD, Dahl O, Klepp O, Wist EA et al (2005) Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 23(22):4980–4990CrossRefPubMed

55.

Nuver J, Smit AJ, van der Meer J, van den Berg MP, van der Graaf WT, Meinardi MT et al (2005) Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 23(36):9130–9137CrossRefPubMed

56.

Brydoy M, Fossa SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T et al (2005) Paternity following treatment for testicular cancer. J Natl Cancer Inst 97(21):1580–1588CrossRefPubMed

57.

Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H et al (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97(18):1354–1365CrossRefPubMed

58.

Schefer HMS, Borner M (2000) Single course adjuvant bleomycin, etoposide and cisplatin for high risk, stage 1 non-seminomatous germ cell tumours (NSGCT). Proc Am Soc Clin Oncol 19:340

59.

Tandstad TDO, Cohn CG, Cavallin-Stahl E, Stierner U, Solberg A, Langberg C, Bremnes R, Klepp O (2007) Risk-adapted treatment in clinical stage 1 (CS1), non-seminomatous germ cell testicular cancer (NSGCT). Eur J Cancer 5(4):302CrossRef

60.

Gilbert DC, Norman AR, Nicholl J, Dearnaley DP, Horwich A, Huddart RA (2006) Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapy. BJU Int 98(1):67–69CrossRefPubMed

61.

Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A et al (2008) Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 26(18):2966–2972CrossRefPubMed

62.

Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R (1993) Retroperitoneal lymphadenectomy for clinical stage a testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol 149(2):237–243PubMed

63.

Stephenson AJ, Bosl GJ, Bajorin DF, Stasi J, Motzer RJ, Sheinfeld J (2005) Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol 174(2):557–560 discussion 60CrossRefPubMed

64.

Jewett MA, Kong YS, Goldberg SD, Sturgeon JF, Thomas GM, Alison RE et al (1988) Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol 139(6):1220–1224PubMed

65.

Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R (1993) Primary retroperitoneal lymph node dissection in clinical stage a non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965-1989. Br J Urol 71(3):326–335CrossRefPubMed

66.

Donohue JP, Foster RS, Rowland RG, Bihrle R, Jones J, Geier G (1990) Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol 144(2 Pt 1):287–291 discussion 91-2PubMed

67.

Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH (1995) Late relapse of testicular cancer. J Clin Oncol 13(5):1170–1176PubMed

68.

Baniel J, Foster RS, Einhorn LH, Donohue JP (1995) Late relapse of clinical stage I testicular cancer. J Urol 154(4):1370–1372CrossRefPubMed

69.

Yoon GH, Stein JP, Skinner DG (2005) Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle: an update. Urol Oncol 23(3):168–177CrossRefPubMed

70.

Heidenreich A, Albers P, Hartmann M, Kliesch S, Kohrmann KU, Krege S et al (2003) Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol 169(5):1710–1714CrossRefPubMed

71.

Rassweiler JJ, Scheitlin W, Heidenreich A, Laguna MP, Janetschek G (2008) Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective Eur Urol 54(5):1004–1015CrossRefPubMed

Titel: Current Concepts in Management of Stage I NSGCT
verfasst von: Puneet Ahluwalia
Gagan Gautam
Publikationsdatum: 17.12.2016
Verlag: Springer India
Erschienen in: Indian Journal of Surgical Oncology / Ausgabe 1/2017
Print ISSN: 0975-7651
Elektronische ISSN: 0976-6952
DOI: https://doi.org/10.1007/s13193-016-0588-z

Neu im Fachgebiet Chirurgie

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Magnetic Resonance Imaging and the Use in Small Renal Masses

Organ Preservation Surgery for Carcinoma Penis

Current Concepts in the Management of Muscle Invasive Bladder Cancer

Desk of the Editor Vol.8 Issue 1

Prognostic Benefit of Surgical Management of Renal Cell Carcinoma Invading the Inferior Vena Cava

Primary Testicular Leiomyosracoma with Local Recurrence: a Case Report

Update Chirurgie